Diagnostic Kits/Paper: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 16: | Line 16: | ||
=== Overview of IP Landscape === | === Overview of IP Landscape === | ||
:''from [[Overview_of_Economics_of_Intellectual_Property_in_Kits]] see overview]'' | |||
==== Patent Protection ==== | ==== Patent Protection ==== | ||
===== Bayh-Dole ===== | ===== Bayh-Dole ===== | ||
Revision as of 12:43, 3 December 2009
Are patents clogging the pipeline: The effects of intellectual property on commercialization and access to genetic diagnostics
(A Summary Paper of our Research to date)
By Carolina Rossini, Andrew Clearwater, and Mackenzie Cowell
Last Draft: December 3, 2009
Introduction
Description of the GDx Market
Defining Genetic Diagnostics
Brief History of GDx and Related Technology
- chemical patents at turn of century (see Palombi's work)
Overview of IP Landscape
- from Overview_of_Economics_of_Intellectual_Property_in_Kits see overview]
Patent Protection
Bayh-Dole
Licensing
When IP Does and Does Not Work Effectively
Our Research Questions
Our Methodology
Forces affecting the GDx Industry
- Revolutionary technical advances
- Regulatory process
- payer system (public & private insurance)
Existing and Evolving GDx Models
Commercialization of Basic Research
- Licensing of research to existing GDx company
- Licensing of research to new GDx start-up
- Usage of research in public domain by existing GDx company? (multiplex kits?)
Paths to Market
- ASRs
- Kits
- DTC